Introduction
Upper tract urothelial carcinoma (UTUC) is an uncommon disease and accounts for 7% to 8% of all renal tumors and 5% to 10% of all urothelial carcinomas [1] [2] . The standard option for UTUC treatment remains radical nephroureterectomy (RNU) because of the aggressiveness of the disease. However, segmental ureterectomy (SU) is increasingly being chosen for better preservation of postoperative renal function, especially for patients with chronic renal insufficiency, solitary kidney or bilateral synchronous disease [3] [4] [5] . To our knowledge, cancer-specific survival (CSS) and recurrence-free survival after SU is not clear, and the indication of SU is debatable.
Here we compared oncologic outcomes by surgery type (SU vs RNU) in a large cohort of patients with UTUC of the distal ureter, which could be meaningful for management of UTUC.
Methods

Patients
A series of 931 UTUC patients who had undergone surgery at our institution from January 2000 to April 2014 was retrospectively analyzed. We included 248 patients with tumors localized at the distal ureter (defined as below the level of iliac vessels) and who underwent SU or RNU. We excluded patients with evidence of metastatic disease at the time of diagnosis, other malignancies or incomplete follow-up data. For patients who were followed at our institute, the follow-up regimen included cystoscopy every 3 months for the first 2 years. The follow-up intervals were extended to half a year up to 5 years after surgery and 1 year thereafter. Chest X-ray, urine cytology, serum creatine measurement, and abdominal ultrasonography or CT/MRI were performed at the same time.
Statistical analysis
Patients were divided into 2 groups by surgery type, SU or RNU. CSS, overall survival (OS), local recurrence-free survival, intravesical recurrence-free survival (IVRFS), contralateral recurrence-free survival and distant metastasis-free survival were analyzed by the Kaplan-Meier method with the log-rank test.
Univariable analysis with the log-rank test and multivariable analysis with the Cox proportional-hazards regression model were used, estimating hazard ratios (HRs) and 95% confidence intervals (CIs). Two-tailed p<0.05 was considered statistically significant.
Results
Clinicopathological characteristics
The clinical and pathological characteristics of the 219 patients included are in Table   1 and Table 2 
CSS and OS
The mean follow-up time (months) did not differ between RNU and SU groups (58.1±8.1 vs 63.7±3.4, p=0.462), and CSS and OS did not differ (p=0.358 and p=0.206) (Fig. 1) .
On multivariable analysis, age, history of UTUC and tumor length were significantly associated with both CSS and OS (Table 3 ). However, the surgery type, RNU or SU, did not predict CSS (HR=0.862, 95% CI 0.469-1.585, p=0.633) or OS (HR=0.764, 95% CI 0.419-1.392, p=0.379).
Recurrence and distant metastasis
The 5-year local recurrence-free survival was 96.2% and 86.0% with RNU and SU (p=0.02) (Fig. 2a) . On multivariable analysis, local recurrence-free survival was associated with SU (HR=5.069, 95% CI 1.029-24.968, p=0.046) ( Table 4 ). The 5-year IVRFS was 45.4% and 46.4% with RNU and SU (p=0.661) (Fig. 2b) . On multivariable analysis, IVRFS was associated with history of bladder carcinoma (HR=2.129, 95% CI 1.385-3.273, p=0.001) and tumor necrosis (HR=2.12, 95% CI 1.212-3.708, p=0.008). The 5-year contralateral recurrence-free survival with RNU and SU was 89.6% and 92.9% (p=0.183) (Fig. 2c) . On multivariable analysis, contralateral recurrence-free survival was associated with age and BMI of patients and tumor length. The 5-year distant metastasis-free survival with RNU and SU was 96.0% and 90.3% (p=0.078) (Fig. 2d) . On multivariable analysis, distant metastasis-free survival was associated with SU (HR=6.497, 95% CI 1.196-35.283, p=0.03).
On stratification by T stage (pTa-T2 vs pT3-T4), CSS, OS, contralateral recurrence-free survival, IVRFS and distant metastasis-free survival did not differ by RNU or SU (data not shown). For patients with pTa-T2, local recurrence-free survival did not differ by surgery type (p=0.296) (Fig. 3) . However, for patients with pT3-T4, local recurrence-free survival was shorter with SU than RNU (p=0.006) (Fig. 3) . The site of local recurrence after SU in the three patients was ureteral residue. Two of the three patients took further surgery and the other one patient took chemotherapy for treatment.
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We aimed to compare oncologic outcomes by surgery type (SU vs RNU) in a large cohort of patients with UTUC of the distal ureter. Long-term oncologic outcomes were equivalent with SU and RNU in patients with UTUC of the distal ureter. SU affected local recurrence survival and distant metastasis survival. Local recurrence-free survival was lower with SU than RNU for patients with advanced disease stage.
In the 2017 European Association of Urology Guidelines, RNU is the standard for high-risk UTUC, regardless of tumor location [6] . In low-risk cancers, which are unifocal, small, low-grade and with no infiltration seen on CT or urography, survival with kidney-sparing surgery (i.e., ureteroscopy or SU) is similar to that with RNU [7] .
In high-risk cancers, kidney-sparing surgery can also be considered with renal insufficiency or solitary functional kidney [3, 8] . As compared with SU, ureteroscopy has several drawbacks such as lack of pathological specimens if treated by laser generator and lymphadenectomy is not possible, which is important in evaluating the stage and grade [8, 9] . Thus, SU is favoured instead of RNU in some situations. However, cancer-specific and recurrence-free survival was unknown with SU.
A retrospective study of more than 2000 patients with UTUC showed no significant difference in cancer-specific survival with SU and RNU [8] . Another study revealed that SU or RNU was not a predictor of CSS on multivariable analysis and CSS or recurrence-free survival did not differ on Kaplan-Meier analyses [10] . Few studies of survival and recurrence for tumors at the distal ureter have been reported. Whether SU could be used in high-risk tumors is still controversial. Bin et al. [11] showed no significant difference in CSS with proximal, middle, or distal tumor location of ureter UTUC.
In our study, the clinicopathologic characteristics of patients with SU and RNU, including TNM stage and tumor grade, did not differ, so the results of CSS, OS and recurrence-free survival were less influenced. The surgery type, SU and RNU, did not affect CSS or OS. Several studies also found CSS and OS comparable with SU and RNU in patients with UTUC of the distal ureter [7, 12, 13] . Furthermore, we found older age, advanced T stage, and length of tumor associated with CSS and OS with UTUC, which agreed with results from the literature.
The two groups did not differ in rate of local recurrence, bladder recurrence, contralateral recurrence and distant metastasis. The rate of bladder recurrence after RNU for UTUC is 22% to 47% [7, 14] . However, we found a bladder recurrence rate of 57.0% with RNU and 55.0% with SU. Lower ureter lesion was previously found an
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Jia et al Title independent predictor of bladder recurrence in patients with UTUC treated with RNU [15] , which may explain why we found a higher rate of bladder recurrence. A systematic review and meta-analysis of bladder recurrence after RNU found ureteral location, necrosis, a laparoscopic approach, intravesical bladder-cuff removal and positive surgical margins linked to bladder recurrence. Ureteral tumor location was a significant predictor of bladder recurrence (HR=1.27, 95% CI 1.14-1.42, p<0.001) [7] . Fradet et al [14] showed tumors located at both the renal pelvis and ureter, older age and laparoscopic surgery as risk factors of bladder recurrence after RNU. Our study found that surgery type, SU or RNU, was not associated with IVRFS, but IVRFS could be predicted by history of bladder carcinoma and tumor necrosis, which agreed with the literature. Furthermore, Liu et al. [16] , in a retrospective analysis of 664 UTUC patients who underwent RNU, found diagnostic ureteroscopy as an independent risk factor of IVRFS. The Sung et al. study had a similar conclusion [17] .
Few studies have investigated local recurrence-free, contralateral-free and distant metastasis-free survival. Hung et al. showed no significant differences in local recurrence-free survival (p=0.302) and distant metastasis-free survival (p=0.219) with SU and RNU [18] . In our study, local recurrence-free survival was lower with SU than RNU, and SU was associated with reduced distant metastasis-free survival. The two groups did not differ in contralateral recurrence-free survival. The tumors investigated in the Hung et al. study were in the whole ureter, whereas our tumors were at the distal ureter, which may explain the differences in results.
Local recurrence-free survival was lower with SU than RNU for patients with pT3-4 stage, but with no effect on CSS, OS, IVRFS, contralateral-free survival or distant metastasis-free survival versus RNU. The Jeldres et al. study showed no difference in CSS with RNU versus SU in patients with pT1-2N0M0 and pT3-4N0M0 [8] . Other researchers implied that patients with locally advanced stage disease should not be excluded from consideration for SU [8, 13] .
The most important advantage of SU might be its better protection of postoperative renal function. SU could contribute to good preservation of renal function [19] . We have few studies about the relation between renal function and prognostic outcomes of patients with UTUC. One study showed decreased glomerular filtration rate after RNU, and renal function was not associated with disease recurrence, CSS or OS. Furthermore, the results were similar when restricted to patients with locally advanced disease (pT3-pT4) [20] .
A systematic review and meta-analysis showed that cisplatin-based adjuvant systemic chemotherapy was beneficial for OS and disease-free survival with UTUC;
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This study was the most comprehensive of the prognostic outcomes of patients with UTUC in the distal ureter with SU and RNU because we investigated CSS, OS, local recurrence-free survival, IVRFS, contralateral recurrence-free survival, and distal metastasis-free survival and in different tumor stages. The major limitation of our study was its single-center retrospective design. A multicenter randomized controlled trial is needed to investigate the prognostic difference of SU and RNU and the proper indications of SU.
Conclusions
Our study suggests that SU and RNU have equivalent long-term prognostic outcomes for patients with UTUC of the distal ureter. However, SU can affect local recurrence survival and distant metastasis survival. With advanced T stage, local recurrence-free survival is lower with SU than RNU. Thus, SU could be used for low-risk tumors similar to RNU and should not be excluded in patients with advanced disease. Patients who underwent SU need to be followed up carefully. Fig. 1 
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